Advaxis Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
52.83 M |
Public Float |
41.4 M |
Advaxis Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$7.26 |
Market Cap |
$14.36 M |
Shares Outstanding |
8.01 M |
Public Float |
64.28 M |
Address |
305 College Road East Princeton New Jersey 08540 United States |
Employees | - |
Website | http://www.advaxis.com |
Updated | 07/08/2019 |
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy, and hotspot mutation therapy. |